Copyright
©The Author(s) 2015.
World J Hepatol. Jul 18, 2015; 7(14): 1843-1855
Published online Jul 18, 2015. doi: 10.4254/wjh.v7.i14.1843
Published online Jul 18, 2015. doi: 10.4254/wjh.v7.i14.1843
Table 3 The recommended for treatment of hepatitis C virus infection by genotype in treatment-naïve patients and in treatment naïve patients with compensated cirrhosis[22]
Genotype | Recommended regimen and duration | Recommended regimen for compensated cirrhosis (CP-A) and duration |
1a | Three options with similar efficacy: | Three options with similar efficacy: |
(1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk | (1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk | |
(2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk | (2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk | |
(3) Daily SOF (400 mg) plus SMV (150 mg) with or without weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk | (3) Daily SOF (400 mg) plus sMV (150 mg) with or without weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 24 wk | |
1b | Three options with similar efficacy: | Three options with similar efficacy: |
(1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk | (1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk | |
(2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) for 12 wk | (2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) plus twice-daily dosed dasabuvir (250 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk | |
(3) Daily SOF (400 mg) plus SMV (150 mg) with or without weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for12 wk | (3) Daily SOF (400 mg) plus SMV (150 mg) with or without weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 24 wk | |
2 | SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk | SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 16 wk |
3 | (1) SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 24 wk | |
(2) Alternative for IFN eligible: SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 12 wk | ||
4 | Three options with similar efficacy and 2 alternatives available: | |
(1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk | ||
(2) Daily fixed-dose combination of paritaprevir (150 mg)/ritonavir (100 mg)/ombitasvir (25 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk | ||
(3) Daily SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 24 wk | ||
(4) Alternative 1 for IFN eligible: Daily SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 12 wk | ||
(5) Alternative 2 for IFN eligible: Daily SOF (400 mg) plus SMV (150 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] for 12 wk | ||
5 | (1) Daily SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 12 wk | |
(2) Alternative 1 for IFN eligible: Weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 48 wk | ||
6 | (1) Daily fixed dose LDP (90 mg)/SOF (400 mg) for 12 wk | |
(2) Alternative 1 for IFN eligible: Daily SOF (400 mg) and weight-based RBV [1000 mg (< 75 kg) to 1200 mg (≥ 75 kg)] plus weekly peg IFN for 12 wk |
- Citation: Khullar V, Firpi RJ. Hepatitis C cirrhosis: New perspectives for diagnosis and treatment. World J Hepatol 2015; 7(14): 1843-1855
- URL: https://www.wjgnet.com/1948-5182/full/v7/i14/1843.htm
- DOI: https://dx.doi.org/10.4254/wjh.v7.i14.1843